Agilent Technologies (A) Stock

A's results for the fourth quarter of 2024 are boosted by high demand in the ACG segment. However, there are worries due to falling sales in the Americas and China markets.

I maintain a "Buy" recommendation for Agilent Technologies, Inc., setting a target price of $150 per share for the next year, due to its strategic growth and market recovery. The purchase of BIOVECTRA will strengthen Agilent's CDMO business, particularly in oligonucleotides and CRISPR therapies, while also broadening its peptide synthesis services. For fiscal year 2025, Agilent expects core revenue growth of 2.5%-3.5% and adjusted EPS growth of 5.8%, which aligns with market expectations and is backed by targeted growth strategies in different segments.

The main figures for Agilent (A) provide an overview of the company's performance for the quarter that ended in October 2024. However, it could be helpful to compare some important metrics with Wall Street predictions and the results from the same period last year.

Agilent Technologies (A) reported quarterly earnings of $1.46 per share, which is higher than the Zacks Consensus Estimate of $1.41 per share. This is an increase compared to earnings of $1.38 per share from the same period last year.

On Monday, Agilent predicted that its yearly profit would be lower than what analysts expected, as the market for medical tools and equipment used in clinical studies is still recovering. This news caused its shares to drop by over 2% after trading hours.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced that its revenue for the fourth quarter ending October 31, 2024, was $1.70 billion, which is a 0.8% increase but a 0.3% decrease in core revenue compared to the same quarter in 2023. The company's GAAP net income for the fourth quarter was $351 million, or $1.22 per share, down from $475 million, or $1.62 per share, in the fourth quarter of the previous fiscal year. Additionally, the non-GAAP net income was $418 million, translating to $1.46 per share for the quarter.

A's performance in the fourth quarter is likely to have improved due to the expanding ACG segment. However, decreasing sales in the end market and across different regions are causing some worries.

Agilent Technologies, Inc. A will announce its earnings for the fourth quarter on Monday, November 25, after the market closes.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) has introduced its latest Agilent InfinityLab LC Series, which features the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all available in biocompatible versions. These are the first high-performance liquid chromatography (HPLC) systems to incorporate the new Agilent InfinityLab Assist Technology, which provides improved built-in support for users. This innovative technology enables.